-transparent.png){kind=logo}
We assessed antitumor activity and toxic effects of cisplatin and 5-day continuous infusion vinblastine in 25 evaluable patients with metastatic breast carcinoma refractory to one or more chemotherapeutic regimens. We administered cisplatin at 70 mg/m2 i.v. followed by vinblastine 1.5 mg/m2 daily for five consecutive days. In our heavily pretreated, poor performance patient population, we observed one complete response and four partial responses, with a median time to progression of 35 weeks. Toxic effects were significant and prevented dosage escalation. The addition of cisplatin does not appear to improve the therapeutic value of vinblastine alone.
Related Publications
G Fraschini, and
F A Holmes, and
A U Buzdar, and
V Hug, and
G N Hortobagyi
October 1987,
Cancer,
G Fraschini, and
F A Holmes, and
A U Buzdar, and
V Hug, and
G N Hortobagyi
October 1982,
American journal of clinical oncology,
G Fraschini, and
F A Holmes, and
A U Buzdar, and
V Hug, and
G N Hortobagyi
January 1985,
Cancer treatment reports,
G Fraschini, and
F A Holmes, and
A U Buzdar, and
V Hug, and
G N Hortobagyi
January 1991,
Chemotherapy,
G Fraschini, and
F A Holmes, and
A U Buzdar, and
V Hug, and
G N Hortobagyi
January 1980,
Cancer treatment reports,
G Fraschini, and
F A Holmes, and
A U Buzdar, and
V Hug, and
G N Hortobagyi
February 1988,
American journal of clinical oncology,
G Fraschini, and
F A Holmes, and
A U Buzdar, and
V Hug, and
G N Hortobagyi
July 1985,
Cancer,
G Fraschini, and
F A Holmes, and
A U Buzdar, and
V Hug, and
G N Hortobagyi
May 1987,
Cancer treatment reports,
G Fraschini, and
F A Holmes, and
A U Buzdar, and
V Hug, and
G N Hortobagyi
February 1987,
Gynecologic oncology,
G Fraschini, and
F A Holmes, and
A U Buzdar, and
V Hug, and
G N Hortobagyi
August 2000,
Annals of oncology : official journal of the European Society for Medical Oncology,
